Willis-Knighton Health System in Shreveport is one of 400 sites conducting clinical trials for an oral medication to prevent COVID illness for those who are exposed to the virus by someone in their household. Principal investigator Dr. Joseph Bocchini, Jr. said this is a critical advance in outpatient therapy.
“Expanding the oral therapy to include individuals who are exposed to prevent them from developing infection would be another important advance in our outpatient management of COVID,” said Bocchini.
The Pfizer medication being used has already received Emergency Use Authorization from the FDA for those who are more susceptible to severe COVID complications. Bocchini said the trial is looking for participants who are exposed to COVID by someone in their household to compare efficacy and dosage.
“Compare outcome to prior studies and to compare five days of treatment to ten days of treatment to determine the duration of treatment that might be needed,” said Bocchini.
The trial is looking for those 18 and older with no current symptoms of COVID and who reside in the same household as someone with symptoms of COVID. Bocchini said participants will be compensated.
“Please contact us, we’re more than happy to discuss it with them and to determine whether they are qualified and we’ll make it easy as possible for them to get involved,” said Bocchini.
For more information call 318-212-8130 or click here.
Comments